Published in Antimicrob Agents Chemother on September 15, 2014
Trehalose pathway as an antifungal target. Virulence (2016) 1.17
VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. Antimicrob Agents Chemother (2015) 0.92
Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother (2015) 0.91
The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrob Agents Chemother (2016) 0.88
Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models. Antimicrob Agents Chemother (2015) 0.86
A complex game of hide and seek: the search for new antifungals. Medchemcomm (2016) 0.82
New facets of antifungal therapy. Virulence (2016) 0.78
Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi. Antimicrob Agents Chemother (2015) 0.78
Azole Antifungal Agents To Treat the Human Pathogens Acanthamoeba castellanii and Acanthamoeba polyphaga through Inhibition of Sterol 14α-Demethylase (CYP51). Antimicrob Agents Chemother (2015) 0.78
The antifungal pipeline: a reality check. Nat Rev Drug Discov (2017) 0.77
Fungal CYP51 Inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother (2016) 0.76
Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14α-demethylase. Sci Rep (2016) 0.76
Crystal structure of the new investigational drug candidate VT-1598 in complex with Aspergillus fumigatus sterol 14α-demethylase provides insights into its broad-spectrum antifungal activity. Antimicrob Agents Chemother (2017) 0.76
VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection. Antimicrob Agents Chemother (2015) 0.75
Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs. Antimicrob Agents Chemother (2017) 0.75
The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through its Inhibition of T. rubrum CYP51. Antimicrob Agents Chemother (2017) 0.75
Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist (2017) 0.75
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta (1969) 4.94
Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother (1985) 4.68
Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Methods Enzymol (1978) 3.43
Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc Natl Acad Sci U S A (1991) 2.75
Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother (2005) 2.62
Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell (2007) 2.25
Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals. Biochem Biophys Res Commun (1989) 2.02
Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet (1996) 1.85
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther (2005) 1.74
Structural basis of human CYP51 inhibition by antifungal azoles. J Mol Biol (2010) 1.67
Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol Lett (1995) 1.66
Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections. J Biol Chem (2009) 1.60
Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother (2010) 1.51
Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis (2010) 1.49
Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos (2002) 1.47
Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase. Biochem Pharmacol (2008) 1.45
Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull (2005) 1.42
Ligand interactions with cytochrome P-450. I. Binding of primary amines. Biochemistry (1969) 1.25
Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common. Drug Metab Dispos (2007) 1.21
The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet (2008) 1.16
Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother (1996) 1.15
Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett (2014) 1.14
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrob Agents Chemother (2010) 1.09
Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus. Arch Biochem Biophys (1997) 1.08
The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo. J Lipid Res (2009) 1.08
A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole. Antimicrob Agents Chemother (2007) 1.06
Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Antimicrob Agents Chemother (2013) 1.03
The N-terminal membrane domain of yeast NADPH-cytochrome P450 (CYP) oxidoreductase is not required for catalytic activity in sterol biosynthesis or in reconstitution of CYP activity. J Biol Chem (1998) 1.03
Invasive candidiasis in immunocompromised hospitalized patients. Arch Med Res (2005) 1.02
Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrob Agents Chemother (2012) 0.97
Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus. Antimicrob Agents Chemother (2008) 0.96
Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob Agents Chemother (2012) 0.96
Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica (2011) 0.94
Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Clin Chim Acta (2013) 0.92
Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J Biomol Screen (2002) 0.91
Assessing pregnancy risks of azole antifungals using a high throughput aromatase inhibition assay. Endocr Res (2002) 0.87
VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. Antimicrob Agents Chemother (2015) 0.92
Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother (2015) 0.91
Fungal CYP51 Inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother (2016) 0.76